To assess the safety and effectiveness of eribulin in clinical settings in Japan, a post-marketing observational study was conducted in patients with HER2-negative advanced breast cancer, which showed favorable results consistent with the results of clinical trials and real-world studies [4, 5]. Here, ERBB2 is linked to breast cancer.